DECABID Drug Patent Profile
When do Decabid patents expire, and when can generic versions of Decabid launch?
Decabid is a drug marketed by Lilly and is included in one NDA.
The generic ingredient in DECABID is indecainide hydrochloride. There is one drug master file entry for this compound. Additional details are available on the indecainide hydrochloride profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for DECABID?
- What are the global sales for DECABID?
- What is Average Wholesale Price for DECABID?
Summary for DECABID
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 26 |
| Patent Applications: | 71 |
| DailyMed Link: | DECABID at DailyMed |
US Patents and Regulatory Information for DECABID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-002 | Dec 29, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-003 | Dec 29, 1989 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for DECABID
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-003 | Dec 29, 1989 | 4,382,093 | ⤷ Start Trial |
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-001 | Dec 29, 1989 | 4,382,093 | ⤷ Start Trial |
| Lilly | DECABID | indecainide hydrochloride | TABLET, EXTENDED RELEASE;ORAL | 019693-002 | Dec 29, 1989 | 4,382,093 | ⤷ Start Trial |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for DECABID
See the table below for patents covering DECABID around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Argentina | 225526 | UN PROCEDIMIENTO PARA PREPARAR 9-HIDROXI-O-AMINOALQUILFLUORENOS Y SUS SALES | ⤷ Start Trial |
| Argentina | 227318 | UN PROCEDIMIENTO PARA PREPARAR 9-CIANO-9-AMINOALQUIL-FLUORENOS V SUS SALES | ⤷ Start Trial |
| Argentina | 228059 | UN PROCEDIMIENTO PARA PREPARAR 9-CARBOXAMIDA-9-AMINOALQUIL FLUORENOS Y SUS SALES | ⤷ Start Trial |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2026 - 2027
NCE-1 Patent Challenge Dates 2026 - 2027
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2026, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch